KRAS is a mutation in 90% of pancreatic cancer patients during which a substitution in the 12th amino acid (replacement of glycine with aspartate) has occurred (KRASG12D), and this mutation plays an essential role in tumor proliferation and metastasis (162). Here, KRAS is linked to pancreatic neoplasm.